FIGURE 3.

Combination of farnesyl-transferase inhibition with KRAS G12D targeting in MRTX1133 resistant PANC1. 6-day combination therapy of tipifarnib and MRTX1133 was applied to 2D cultures of PANC1 cells. (A) Control-normalized viability values. Data are derived from three independent experiments and are expressed relative to control (n = 3, ±SEM) (B) Synergy map calculated from viability results using synergyfinder.org. In general, a synergy score greater than 10 is considered to have synergistic effects. Note that the most synergistic area is at low dose tipifarnib and high dose MRTX1133.